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those subjected to HT as a ﬁrst choice.
OS of 70% was reported at 40 months. OS and DFS for chil-
dren with leukemia was 75% and 40%, respectively. For
children with immunodeﬁciencies it was 65% and 15%,
respectively, with a 40-month follow-up321
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Purpose: Cytomegalovirus (CMV) infection remains a sig-
niﬁcant source of morbidity in pediatric hematopoietic stem
cell transplantation (HSCT). Current strategies for mitigating
the effect of CMV on outcome include weekly measurement
of CMV viral load in the blood through post-transplant day
100 and use of acyclovir prophylaxis in the peritransplant
period in patients at risk for CMV infection (patients inwhich
the HSCT donor or recipient had CMV IgG seropositivity
indicative of latent infection). Risk factors predicting CMV
infection in pediatric HSCT are not well understood, and
factors affecting recurrence of CMV viremia following an
initial episode have not been reported.
Methods: We performed a retrospective review of consec-
utive cases at our institution between 2011 and 2014 where
the recipient was at risk for CMV infection. We calculated
odds ratios (OR) and 95% conﬁdence intervals (CI) of CMV
reactivation as a function of HSCT characteristics. This study
was approved by the Institutional Review Board of the Dana-
Farber Cancer Institute.
Results: Out of a total of 91 at risk patients, 26 (29%) pa-
tients had CMV infection (deﬁned as CMV viremia without
target organ involvement) occurring at a median of 46 days
following HSCT (range: 9-127). One patient died from bi-
opsy-proven CMV pneumonitis. There was a trend towards
recipients with underlying malignant conditions having
increased risk of CMV infection compared to others
(OR¼2.3; 95% CI¼0.9-6.0; p¼0.08). There was a signiﬁ-
cantly increased risk of CMV infection in recipients of an
umbilical cord blood compared to other sources (OR¼9.45;
95% CI¼1.8-50.6; p¼0.009). Patients with acute graft-
versus-host disease (aGVHD) had a signiﬁcantly increased
risk of CMV infection (OR¼3.6; 95% CI¼1.1-12.1; p¼0.04).
All patients with viremia received a 14-day course of
antiviral and immunoglobulin therapy. Patients who failed
to clear the virus completely from the blood at the end of
14 days of therapy had no increased risk of CMV recurrence
(p¼0.2). A total of 6/26 (23%) HSCT recipients experienced
CMV recurrence, at a median of 33 days (range 9-74)
following initial CMV clearance. In the subset of recipients
who experienced a recurrence of CMV infection, there was
a trend toward increased treatment-related mortality
(TRM; OR¼9.5; 95% CI ¼ 0.7-132; p¼0.09). However,
among all recipients at risk, CMV viremia was not associ-
ated with increased TRM (p¼0.7).
Conclusions: Pediatric patients seropositive for CMV who
receive umbilical cord HSCTs have increased risk for CMV
viremia in the post-HSCT period. CMV infection is associ-
ated with aGVHD. If treated with antivirals, recurrence of
CMV can be prevented. Multiple episodes of CMV viremiamay be associated with increased TRM. This study
broadens understanding of CMV disease in pediatric HSCT,
and is the ﬁrst to analyze factors inﬂuencing recurrence of
CMV infection.322
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Familial hemophagocytic lymphohistiocytosis (FHLH) has
often been associated with high transplant-relatedmortality,
typically from a variety of causes in the ﬁrst 100 days post-
HSCT. We report a case of occult pulmonary hypertension
that developed 3 years after HSCT for FHLH. The patient was
born at 28 weeks with a NICU course consisting of mild
respiratory distress syndrome and unilateral grade II intra-
ventricular hemorrhage. At 2.5 months of age, he developed
fevers, splenomegaly, progressive pancytopenia, hypoﬁ-
brinogenemia, hyperferritinemia, and bone marrow hemo-
phagocytosis. He underwent initial treatment per HLH-2004
with good response. Genetic analysis revealed homozygous
perforin 1 mutations. He proceeded with a 5/6 cord blood
transplant with Bu/Cy/VP-16/ATG conditioning and GVHD
prophylaxis with cyclosporine and steroids. He achieved
successful engraftment with stable 100% donor chimerism.
Post-HSCT course was complicated by engraftment syn-
drome, steroid-responsive grade II skin and gut aGVHD, se-
vere VOD treatedwith deﬁbrotide, and prolonged intubation.
He developed persistent renal failure, presumably due to
chronic calcineurin toxicity. He underwent cadaveric renal
transplant 10 months after HSCT. Clinical care over the next
two years was all outpatient, but complicated by BK
nephropathy.
Two months prior to his death, he presented with
tachypnea and oxygen desaturation. CXR showed mild
peribronchial opacities. Respiratory viral panel and echo-
cardiogram were normal. His symptoms resolved quickly
with albuterol. He was re-admitted a week later with
similar symptoms. Repeat CXR and echocardiogram were
unchanged. Due to persistent symptoms, he underwent
bronchoscopy that was positive for P. jirovecii and was
treated with high-dose Bactrim. One month after
completing treatment, he presented to an outside ER with
acute onset of dyspnea. He rapidly decompensated into
PEA and was unable to be resuscitated. Autopsy showed
intimal and medial thickening of his pulmonary arteries
with marked luminal narrowing, consistent with pulmo-
nary arterial hypertension (PAH).
There is one prior case report of two pediatric FHLH patients
who died in the ﬁrst year post-HSCT with PAH discovered on
autopsy. Despite successful HSCT, there appears to be a
pathologic link between FHLH and PAH, both early and late
post-HSCT. PAH should be considered in any FHLH patient
with respiratory symptoms and improved screening tech-
niques are critically needed.
